Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis

References

• Campbell PJ, Green AR. Mechanisms of disease: the myelo1proliferative disorders. N Engl J Med 2006;355:2452–2466.
   PubMed Web of Science ®Google Scholar
• Skov V, Larsen TS, Thomassen M, et al. Whole blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol 2011;87:54–60.
   PubMed Web of Science ®Google Scholar
• Skov V, Larsen TS, Thomassen M, et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol 2012;40:771–780.
   PubMed Web of Science ®Google Scholar
• Skov V, Larsen TS, Thomassen M, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res 2012;36: 1387–1392.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?Blood 2012;119:3219–3225.
   PubMed Web of Science ®Google Scholar
• Riley CH, Jensen MK, Brimnes MK, et al. Increase in circulating CD4 + CD25+ Foxp3 + cells in patients with Philadelphia-negative chronic myeloproliefrative neoplasms during treatment with intererferon-alpha. Blood 2011;118:2170–2173.
   PubMed Web of Science ®Google Scholar
• de Castro FA, Palma PV, Morais FR, et al. Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma 2003;44:2061–2067.
   PubMed Web of Science ®Google Scholar
• Gabriele L, Borghi P, Rozera C, et al. IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 2004;103:980–987.
   PubMed Web of Science ®Google Scholar
• Rohon P. Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol 2012;96:1–9.
   PubMed Web of Science ®Google Scholar
• Glauche I, Horn K, Horn M, et al. Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations. Br J Cancer 2012;106: 1742–1752.
   PubMed Web of Science ®Google Scholar
• Brodsky FM, Guagliardi LE. The cell biology of antigen processing and presentation. Annu Rev Immunol 1991;9:707–744.
   PubMed Web of Science ®Google Scholar
• Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89–95.
   PubMedGoogle Scholar
• Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001;83:117–158.
   PubMed Web of Science ®Google Scholar
• Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 2012;22: 350–358.
   PubMed Web of Science ®Google Scholar
• Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 2012 ;61:249–254.
   PubMed Web of Science ®Google Scholar
• Demanet C, Mulder A, Deneys V, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells:an escape mechanism from CTL and NK attack?Blood 2004;103: 3122–3130.
   PubMed Web of Science ®Google Scholar
• Majumder D, Bandyopadhyay D, Chandra S, et al. Analysis of HLA class Ia transcripts in human leukaemias. Immunogenetics 2005;57:579–589.
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010;24:756–764.
   PubMed Web of Science ®Google Scholar
• Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comp Graph Stat 1996;5:299–314.
   Google Scholar
• Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249–264.
   PubMed Web of Science ®Google Scholar
• Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article 3.
   PubMedGoogle Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289–300.
   Google Scholar
• Berkofsky-Fessler W, Buzzai M, Kim MK, et al. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res 2010;16:4339–4352.
   PubMed Web of Science ®Google Scholar
• Nie Y, Yang G, Song Y, et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 2001;22:1615–1623.
   PubMed Web of Science ®Google Scholar
• Serrano A, Tanzarella S, Lionello I, et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2-deoxycytidine treatment. Int J Cancer 2001;94:243–251.
   PubMed Web of Science ®Google Scholar
• Ye Q, Shen Y, Wang X, et al. Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens 2009;75:30–39.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 2009;18:2068–2073.
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011;118:6515–6520.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Toyota M, Kondo Y, et al. Inflammation-related aberrant patterns of DNA methylation: detection and role in epigenetic deregulation of cancer cell transcriptome. Methods Mol Biol 2009; 512:55–69.
   PubMedGoogle Scholar
• Stenvinkel P, Karimi M, Johansson S, et al. Impact of inflammation on epigenetic DNA methylation–a novel risk factor for cardiovascular disease?J Intern Med 2007;261:488–499.
   PubMed Web of Science ®Google Scholar
• Kato S, Lindholm B, Stenvinkel P, et al. DNA hypermethylation and inflammatory markers in incident Japanese dialysis patients. Nephron Extra 2012;2:159–168.
   PubMedGoogle Scholar
• Garrido C, Paco L, Romero I, et al. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis 2012;33:687–693.
   PubMed Web of Science ®Google Scholar
• Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010;116:3735–3742.
   PubMed Web of Science ®Google Scholar
• Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008;22:740–747.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446–455.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica 2011;96:1398–1402.
   PubMed Web of Science ®Google Scholar
• Lykkegaard Andersen C, McMullin MF, Ejerblad E, et al. A phase II study of vorinostat (MK-0683) in patients with polycythemia vera and essential thrombocythemia. Blood 2012;120: Abstract 803.
   Google Scholar
• Hasselbalch HC. A new era for IFN-a in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011;4:637–655.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011;117:4706–4715.
   PubMed Web of Science ®Google Scholar
• Yanai Y, Sanou O, Yamamoto K, et al. The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes. Cancer Lett 2002;185:173–179.
   PubMed Web of Science ®Google Scholar
• Brouwer RE, van der HP, Schreuder GM, et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol 2002;63:200–210.
   PubMed Web of Science ®Google Scholar
• Burchert A, Neubauer A. Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 2005;46:167–175.
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007;89:884–893.
   PubMed Web of Science ®Google Scholar
• Biernacki MA, Marina O, Zhang W, et al. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res 2010;70: 906–915.
   PubMed Web of Science ®Google Scholar
• Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFNalpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010;43:204–209.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Møller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha interferon2b in polycythemia vera: a report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009;14:331–334.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?Leuk Res 2012 Nov 20. [Epub ahead of print]
   Web of Science ®Google Scholar